MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Ionis Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

74.82 -0.4

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

73.18

Максимум

75.02

Ключови измерители

By Trading Economics

Приходи

-100M

-229M

Продажби

46M

203M

Марж на печалбата

-112.808

Служители

1,402

EBITDA

4.7B

4.6B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+29.36% upside

Дивиденти

By Dow Jones

Следващи печалби

29.04.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-1.7B

12B

Предишно отваряне

75.22

Предишно затваряне

74.82

Настроения в новините

By Acuity

50%

50%

166 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

Ionis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.04.2026 г., 17:11 ч. UTC

Значими двигатели на пазара
Значими събития в новините

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2.04.2026 г., 17:10 ч. UTC

Значими събития в новините

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3.04.2026 г., 00:00 ч. UTC

Значими събития в новините

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2.04.2026 г., 23:47 ч. UTC

Пазарно говорене
Значими събития в новините

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2.04.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2.04.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2.04.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2.04.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2.04.2026 г., 21:01 ч. UTC

Значими събития в новините

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2.04.2026 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

Starbucks and Boyu Capital Finalize China JV

2.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

2.04.2026 г., 20:41 ч. UTC

Печалби

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2.04.2026 г., 20:32 ч. UTC

Пазарно говорене

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2.04.2026 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2.04.2026 г., 20:09 ч. UTC

Пазарно говорене

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2.04.2026 г., 20:01 ч. UTC

Придобивния, сливания и поглъщания

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2.04.2026 г., 19:46 ч. UTC

Пазарно говорене

Is Oil the New GameStop? -- Market Talk

2.04.2026 г., 19:35 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2.04.2026 г., 19:29 ч. UTC

Придобивния, сливания и поглъщания

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2.04.2026 г., 19:24 ч. UTC

Пазарно говорене
Значими събития в новините

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2.04.2026 г., 19:20 ч. UTC

Пазарно говорене

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2.04.2026 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2.04.2026 г., 19:00 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific: Agreement Reached With American Train Dispatchers Association

2.04.2026 г., 18:24 ч. UTC

Придобивния, сливания и поглъщания

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2.04.2026 г., 17:44 ч. UTC

Пазарно говорене
Значими събития в новините

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2.04.2026 г., 17:32 ч. UTC

Значими събития в новините

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2.04.2026 г., 17:26 ч. UTC

Печалби

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2.04.2026 г., 17:17 ч. UTC

Пазарно говорене

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2.04.2026 г., 17:09 ч. UTC

Пазарно говорене
Значими събития в новините

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ionis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

29.36% нагоре

12-месечна прогноза

Среден 97.19 USD  29.36%

Висок 120 USD

Нисък 72 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Ionis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

11

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

29.78 / 33.645Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Very Strong Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

166 / 349 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Среден

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat